Pivotal BioVenture Partners

Pivotal BioVenture Partners is a venture capital firm dedicated to investing in innovative companies developing therapeutics to address major unmet medical needs and improve patient lives. Established in 2017, the firm operates under the broader Pivotal Life Sciences group, a global healthcare investment firm with over $2 billion under management. Pivotal BioVenture Partners focuses on companies based in North America and Europe, investing at all stages from seed to publicly listed entities.

The firm's investment strategy centers on identifying groundbreaking, differentiated science from discovery to early clinical development, with the potential to deliver transformative therapies. The team brings together over 50 years of combined biotech venture capital and company-building experience from top-tier funds, including Novo Ventures, TPG Biotech, Bay City Capital, NEA, and SV Life Sciences. This extensive network and expertise enable Pivotal BioVenture Partners to evaluate new investment opportunities, build value in its portfolio, and contribute management talent and referrals to its companies.

Pivotal BioVenture Partners has made 38 investments, with its most recent on July 22, 2025, when Avalyn Pharma raised an undisclosed amount. The firm has raised a total of at least $300 million across its funds. Notable portfolio companies include Karuna Therapeutics, Vaxcyte, Evommune, and Maplight Therapeutics. The firm's investment approach emphasizes leading or co-leading transactions and working alongside entrepreneurs as company builders and active board members, aiming to support portfolio companies throughout their evolution, including in late-stage private rounds, IPOs, and follow-on rounds in the public market.